Correction: Real-World Insights on Multiple Myeloma: Prognostic Importance of 1q21

Overview

This correction addresses inaccuracies in references related to the prognostic significance of 1q21 chromosomal abnormalities in multiple myeloma. Accurate citation of prior studies is crucial for understanding the implications of these genetic factors on patient outcomes.

Background

Multiple myeloma (MM) is a prevalent hematological malignancy characterized by significant biological and genetic heterogeneity. The identification of chromosomal abnormalities, particularly those involving chromosome 1q21, has been associated with poor prognosis. Accurate references are essential for clinicians to understand the implications of these findings in the context of patient management and treatment strategies.

Data Highlights

No numerical or trial data presented in the correction article.

Key Findings

• Correction of multiple references related to 1q21 abnormalities in multiple myeloma.
• Accurate citation of studies linking 1q21 amplification to aggressive clinical courses in MM.
• Importance of recognizing intraclone heterogeneity in the development of myeloma.
• Clarification of the relationship between chromosomal aberrations and patient stratification in treatment.
• Emphasis on the need for precise genomic classification in guiding therapy.

Clinical Implications

Clinicians should ensure they are referencing the most accurate and updated literature regarding chromosomal abnormalities in multiple myeloma. Understanding the implications of 1q21 abnormalities can aid in risk stratification and treatment planning for patients.

Conclusion

This correction highlights the importance of accurate references in the literature concerning multiple myeloma and its associated genetic factors, which are critical for informed clinical decision-making.

Related Resources & Content

1. Sretenovic A, Mitrovic M, Bukumiric Z, et al., Front. Oncol., 2026 -- Correction on Multiple Myeloma in the Real World Settings
2. Blood Cancer Journal — Abnormalities on Chromosome 1q21 in Patients with Multiple Myeloma
3. Blood Cancer Journal — Chromosome 1q Alterations in Multiple Myeloma: A Systematic Review of Randomized Clinical Trials
4. Blood Cancer Journal — Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
5. Blood Cancer Journal — Increased Non-Clonal Plasma Cell Proportion at Diagnosis Correlates with Better Prognosis in Multiple Myeloma
6. Abnormalities on Chromosome 1q21 in Patients with Multiple Myeloma
7. Chromosome 1q Alterations in Multiple Myeloma: A Systematic Review of Randomized Clinical Trials
8. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
9. EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
10. Temporal genomic dynamics shape clinical trajectory in multiple myeloma